1. Home
  2. CLLS vs IPFX Comparison

CLLS vs IPFX Comparison

Compare CLLS & IPFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$1.12

Market Cap

394.4M

Sector

Health Care

ML Signal

N/A

IPFX

Inflection Point Acquisition Corp. VI Class A Ordinary Shares

N/A

Current Price

$10.15

Market Cap

338.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CLLS
IPFX
Founded
1999
2025
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
394.4M
338.0M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
CLLS
IPFX
Price
$1.12
$10.15
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $4.83
N/A
AVG Volume (30 Days)
98.3K
★ 148.4K
Earning Date
11-10-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$9.97
52 Week High
$5.45
$10.64

Technical Indicators

Market Signals
Indicator
CLLS
IPFX
Relative Strength Index (RSI) 38.78 72.20
Support Level $0.88 $10.08
Resistance Level $2.99 $10.40
Average True Range (ATR) 0.10 0.03
MACD 0.07 0.02
Stochastic Oscillator 57.67 90.00

Price Performance

Historical Comparison
CLLS
IPFX

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About IPFX Inflection Point Acquisition Corp. VI Class A Ordinary Shares

Inflection Point Acquisition Corp VI is a special purpose acquisition company.

Share on Social Networks: